One particular reason might be due to the ability of these chemotherapies to regulate the expression of cellular proteins, which may subsequently enhance the transcription of TRAIL receptors, such as DR4 and DR5, leading to the greater sensitivity of tumor cells and CSCs to TRAIL. Here, TNFRSF10B is linked to neoplasm.